Target intelligence / Profile preview

NACHT and WD repeat domain-containing protein 2 (NWD2)

Target
NWD2
Molecular classification
Other (STAND protein family—Signal transduction ATPases with numerous domains), WD repeat-containing protein, NACHT domain-containing protein
01

Overview

NACHT and WD repeat domain-containing protein 2 (NWD2) is a multidomain protein characterized by the presence of a NACHT domain and multiple WD-repeat motifs[1][5][8]. It is a member of the STAND subfamily of P-loop NTPases and is classified as a WD repeat-containing protein, which is a group involved in protein-protein interactions and diverse regulatory cellular functions[3][7]. In mouse, NWD2 expression is mostly confined to neurons in the medial habenular nucleus, with lower levels in brain regions such as the piriform cortex and hippocampus[4]. The exact biological role in humans is not fully established, but by homology and family function, it is likely involved in specialized neuronal signal transduction processes. There is no evidence that NWD2 is a therapeutic target or receptor, nor are there known drugs that interact with it. NWD2 is primarily a gene product involved in cellular signaling rather than a classic drug target like a receptor, enzyme, or ion channel. It is often referenced by its abbreviation (NWD2) and is occasionally listed under older gene symbols such as KIAA1239[1][5]. It has not been implicated in common human diseases, and its function remains under characterization in the neuroscience field.

Other names
KIAA1239Leucine-rich repeat and WD repeat-containing protein KIAA1239NACHT and WD repeat domain containing 2ENSG00000174145
02

Mechanism of action

Not applicable (no known targeted drugs).

03

Biological functions

Signal transductionPossible roles in synaptic activityInvolved in regulatory neuronal processes in the central nervous system, specifically in certain neuronal subtypes
04

Disease associations

No well-established direct disease associations for NWD2. Expression is observed in specific neuronal populations, suggesting possible relevance for psychiatric or neurological conditions, but there is no current evidence for direct causality or utility as a therapeutic target
05

Safety considerations

None known or reported.
06

Interacting drugs

None known or reported.
07

Biomarkers

None known.

Beyond the preview

Go deeper on NACHT and WD repeat domain-containing protein 2 (NWD2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NACHT and WD repeat domain-containing protein 2 (NWD2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call